Sanofi's Dupixent Study Meets Endpoints
Ticker: SNYNF · Form: 6-K · Filed: Nov 18, 2025 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Nov 18, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: drug-development, clinical-trial, press-release
TL;DR
Sanofi's Dupixent study a success, good news for Regeneron.
AI Summary
On November 7, 2025, Sanofi announced that the pivotal study for Dupixent, developed with Regeneron, met all primary and secondary endpoints. This filing is a Form 6-K report for the month of November 2025, incorporating press releases as exhibits.
Why It Matters
Positive study results for Dupixent could lead to expanded use and increased revenue for Sanofi and Regeneron.
Risk Assessment
Risk Level: low — This filing is an informational report and does not contain new financial or strategic information that would significantly alter risk.
Key Players & Entities
- Sanofi (company) — Registrant and developer of Dupixent
- Regeneron (company) — Collaborator on Dupixent
- Dupixent (company) — Drug developed by Sanofi and Regeneron
- November 7, 2025 (date) — Date of press release
FAQ
What type of filing is this?
This is a Form 6-K report filed by Sanofi for the month of November 2025.
What is the main news reported in the attached exhibits?
The main news is that Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints.
What is the filing date of this report?
The filing date is November 18, 2025.
What is Sanofi's primary SIC code?
Sanofi's primary SIC code is 2834, Pharmaceutical Preparations.
What are the incorporated exhibits?
The incorporated exhibits are Press Release dated November 7, 2025 (Exhibit 99.1) and another press release (Exhibit 99.2).
Filing Stats: 224 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2025-11-18 12:29:51
Filing Documents
- d895566d6k.htm (6-K) — 8KB
- d895566dex991.htm (EX-99.1) — 39KB
- d895566dex992.htm (EX-99.2) — 19KB
- g895566g0730220735399.jpg (GRAPHIC) — 3KB
- 0001193125-25-285701.txt ( ) — 71KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: November 18, 2025 SANOFI By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3